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Study Design for Concurrent
Development, Assessment,
and Implementation of
New Diagnostic Imaging
Technology1
With current constraints on health care resources and emphasis on value for money,
new diagnostic imaging technologies must be assessed and their value demon-
strated. The state of the art in the field of diagnostic imaging technology assessment
advocates a hierarchical step-by-step approach. Although rigorous, such a hierar-
chical assessment is time-consuming, and, given the current rapid advances in
technology, results are often too late to influence management and policy decisions.
The purpose of this article is to discuss a study design in which development,
assessment, and implementation of new diagnostic imaging technology take place
concurrently in one integrated process. An empirically based pragmatic study
design is proposed for imaging technology assessment. To minimize bias and enable
comparison with current technology, a randomized controlled design is used when-
ever feasible and ethical. Outcome measures should reflect the clinical decision-
making process based on imaging information and acceptance of the new test.
Outcome measures can include additional imaging studies requested, costs of
diagnostic work-up and treatment, physicians’ confidence in therapeutic decision
making, recruitment rate, and patient outcome measures related to the clinical
problem. The key feature of the proposed study design is analysis of trends in
outcome measures over time.
The rapid advances in diagnostic imaging technology make a thorough assessment of new
technology prior to its implementation a challenge. With the current constraints on
health care resources and the emphasis on value for money, we feel compelled to assess
new technologies and demonstrate their value prior to their widespread use in day-to-day
practice. A hierarchical approach to the assessment of new diagnostic imaging technology
has been advocated and used by technology assessors in the field (Fig 1) (1–12). This
approach entails assessments of technical performance; diagnostic performance; diagnos-
tic, therapeutic, and prognostic effect; effectiveness (patient and societal outcomes); and
cost-effectiveness of the new technology.
The hierarchical approach is rigorous and scientifically sound, but when performed
sequentially it is also time-consuming. We often find that by the time we have performed
the advocated studies, the results of such an assessment are no longer useful. With the
rapid advances in diagnostic imaging technology, either the new test has been imple-
mented in practice because of the “beautiful images” it produces, or it has been discarded
in lieu of an even newer technique that clearly surpasses the one we have been evaluating.
In fact, new diagnostic imaging technologies are often implemented as soon as they are
available, on the basis of subjective experience with a limited number of cases. An
additional problem is that for each modality, new technologic developments, such as new
magnetic resonance (MR) sequences or updated postprocessing software, are constantly
implemented on the basis of subjective expectations of their usefulness.
The goal of developing and assessing new diagnostic imaging technology is presumably
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to implement valuable and affordable
new technology in a timely fashion to
attain our fundamental goal of improv-
ing health. To achieve this goal we feel
the need to perform thorough scientifi-
cally based assessment studies of new di-
agnostic imaging technology prior to its
implementation, to demonstrate that the
technology provides value for money
(13). At the same time, we feel the need
to rapidly implement new diagnostic im-
aging technology, which is why we tend
to base our judgment of the value of new
technology on subjective experience
with a limited number of cases. As dem-
onstrated in Figure 2, these consider-
ations give rise to two apparently dispar-
ate pathways to our goal (14,15). The
diagram represents a closed circle, which
symbolizes the conflict that exists be-
tween the two pathways. As long as the
circle remains closed—that is, as long as
the conflict remains unresolved—tension
will persist. So, how do we resolve this
conflict?
In this article, we address the conflict
between the perceived need for a hierar-
chical assessment of new diagnostic im-
aging technology prior to its implemen-
tation versus the perceived need to
rapidly implement new technology after
a subjective evaluation based on our ex-
perience with a limited number of cases.
To resolve the conflict, we propose a
study design that integrates the develop-
ment, assessment, and implementation
of new diagnostic imaging technology.
CHALLENGING THE
UNDERLYING ASSUMPTIONS
To address the diagramed conflict, we
must identify the underlying assump-
tions and find evidence that could be
used to either support or weaken the as-
sumptions. Let us analyze each arrow in
Figure 2.
(A) Only Thorough Hierarchical
Assessment Will Provide the
Necessary and Relevant
Information
Traditionally, the evaluation of new di-
agnostic imaging technologies has fo-
cused on determining pairs of sensitivity
and specificity (or a receiver operating
characteristic curve) values in compari-
son to a reference standard. This entails
performance of both the new test and the
reference standard test in all patients in a
cohort study and determination of the
probability of abnormal and normal
findings conditional on disease or no dis-
ease (sensitivity and specificity, respec-
tively) or, alternatively, the predicted
probability of disease conditional on the
test result. The reference standard, how-
ever, is not flawless in helping distin-
guish individuals with disease from those
without. For example, intraarterial x-ray
angiography (an invasive procedure in-
volving arterial catheterization) is gener-
ally considered to be the reference stan-
dard for vascular disease but has been
shown to result in missed patent runoff
vessels (16,17). Because computed tomo-
graphic (CT) angiography and MR an-
giography (18–20) provide three-dimen-
sional information, they may surpass
intraarterial angiography. A comparison
of CT angiography or MR angiography
with intraarterial angiography as the ref-
erence standard will, therefore, lead to
underestimation of the sensitivity and
specificity of these new tests because in-
traarterial angiography is defined as the
reference standard, or perfect, test. Fur-
thermore, for some innovative technolo-
gies such as molecular imaging, an ap-
propriate reference standard simply does
not exist because the index test is an at-
tempt to diagnose a condition that is un-
identifiable with existing technology (eg,
cancer in a very early phase).
In addition, if the reference standard
examination is invasive we cannot, on
ethical grounds, perform it in all cases.
This implies that the new test will be
verified in selected cases only, and this,
too, may lead to biased estimates of sen-
sitivity and specificity (21–23). For exam-
ple, in potential living kidney donors,
surgical findings may be considered the
best reference standard, but surgical find-
ings will be available only for those kid-
neys removed for transplantation. Com-
monly, we revert to using a combination
of findings as the reference standard
(24,25). Such an approach inevitably
leads to biases related to the mixed refer-
ence standard and a reference that is not
independent of the tests being evaluated
(21–23). Alternatively, we can use a
mathematical correction method that
adjusts for the potential bias resulting
from selected verification (26–30). This
method does, however, require the as-
sumption that the predictive value of a
test is unaffected by verification bias.
Furthermore, although sensitivity and
specificity may be useful performance pa-
rameters in the initial evaluation of a
new test, they seldom provide the infor-
mation we need to decide whether the
new diagnostic strategy should be imple-
mented. A result indicating that sensitiv-
ity and specificity are both, say, 95% is
difficult to translate into a meaningful
clinical decision. To decide whether the
new diagnostic strategy should actually
replace the current strategy requires stud-
ies to evaluate the effect on decision
making, patient outcomes, and costs.
Decision analysis is a useful tool for
estimating the effect on cost and effec-
tiveness outcomes and for evaluating di-
verse strategies (31–33). Advantages of
decision analysis are the ability to inte-
Figure 1. Schematic shows the hierarchical approach to develop-
ment, assessment, and implementation of new diagnostic imaging
technology. Dx  diagnosis, Px  prognosis, Rx  therapy.
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grate all the available evidence and val-
ues, model a wide range of strategies, and
explore the effect of uncertainty on the
decision. Decision analysis does, how-
ever, have limitations. It is time-consum-
ing to perform properly, it relies on data
from multiple heterogenous sources, it
requires assumptions to make the prob-
lem tractable, and it has limited impact
on everyday clinical practice. A large ran-
domized controlled trial (RCT) with long-
term follow-up of quality-of-life and sur-
vival measures would be scientifically
rigorous, but, because the differences in
quality of life and survival across diagnos-
tic strategies are generally small (34), such
studies must be large, take a long time to
perform, and require substantial resources.
One can question whether the additional
information obtained from such trials jus-
tifies the research resources used (35).
(B) Relevant Information Will Lead
to Implementation of Optimal
Diagnostic Imaging Technology
Even if we have the resources to per-
form a thorough evaluation of a new di-
agnostic imaging technology, implemen-
tation of the study results can pose a
problem. After performing a cohort study
in which both the old test and the new
test are performed in all patients, we sub-
sequently often find ourselves perform-
ing both tests because that is what clini-
cians have become familiar with. Both
physicians and patients assume that more
imaging studies will lead to better diagnos-
tic information. Furthermore, more tests
yielding the same findings increase confi-
dence in the diagnosis. Thus, physicians
will tend to want to use all the possible
diagnostic imaging technologies available.
Four of five times, implementation of new
technology implies that instead of the new
technique replacing the old technique, the
new technique is performed in addition to
the old one (36).
(C) New Imaging Technology Provides
More and Better Diagnostic
Information That Will Lead to Better
Therapeutic Choices and Outcomes
The tremendous increase in the use of
imaging procedures suggests that physi-
cians and patients believe that more and
better diagnostic imaging technology leads
to more and better diagnostic information,
which in turn leads to optimal therapeutic
choices and outcomes. The connection be-
tween more diagnostic imaging informa-
tion and patient outcomes, however, is dif-
ficult to demonstrate because of the
multiple intervening paths and steps (36).
Although the choice of treatment is com-
monly influenced by imaging findings, a
change from a currently used diagnostic
strategy to one that uses a newer technol-
ogy will generally yield only small benefits
to the patient (34). New imaging technol-
ogy can, however, reduce the convales-
cence period through the use of proce-
dures, both diagnostic and therapeutic,
that are less invasive.
(D1) Rapid Advances in New
Diagnostic Imaging Technology
Are Hard to Keep Up With
Rapid technologic advances are a fact.
Not only do we accept this fact, but we
are also generally content with the tech-
Figure 2. Diagram illustrates the conflict between performing a hierarchical assessment versus subjective evaluation of new diagnostic imaging
technology.
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nologic advances, since they bring with
them the possibility of better health care
and a higher standard of living. New
technology is becoming more widely
available, there is a continual increase in
the expertise of those using new technol-
ogy, and there is continual development
of the technology. The pace of the ad-
vances are mind-boggling, and we must
do everything we can to cope with the
technologic changes. In effect, this re-
quires efficient methods of research,
which implies a focus on providing the
information relevant to the clinical deci-
sion-making process.
(D2) Current Technology
Assessment Studies Do Not Provide
Relevant Information in a
Timely Fashion
In this respect we should ask ourselves:
What exactly is the relevant information
in this context? To decide whether a new
technology is valuable and affordable, do
we really need to go through the whole
gamut of the test’s reproducibility; sensi-
tivity; specificity; receiver operating char-
acteristic analysis; effect on diagnostic,
therapeutic, and prognostic thinking; pa-
tient benefit from use of the test; and
cost-effectiveness from a societal perspec-
tive? This is probably not so. In fact, the
only evidence we really need is that use
of the new diagnostic strategy facilitates
the clinical decision-making process
without compromising patient outcomes
and that we can afford to pay for it.
Sometimes a new technology is so ob-
viously better, simpler, less risky, and less
expensive than the established technol-
ogy that an extensive assessment is un-
necessary: A balance sheet of the pros
and cons, taking into account the various
dimensions of the decision, can suffice
(31). For example, head CT did not need
to be extensively assessed in comparison
to pneumoencephalography to demon-
strate its superiority. At the same time,
statements of obvious superiority must
be interpreted with caution: The advocate
of a new technology is usually someone
with his or her own biases and agenda.
Disillusionment frequently follows an
initially optimistic introduction of new
technology. Currently, new technology
is generally only marginally better than
what we have available already, and the
associated price tag may not be justified.
Commonly, the new diagnostic strategy
has both advantages and disadvantages
in comparison with the established tests,
in which case an assessment of its effect
on the clinical process is warranted.
(E) Evaluation of New Diagnostic
Imaging Technology Must Be
Performed before Implementation
With the hierarchical approach, evalu-
ation of a new technology must precede
its implementation. Although this ap-
pears to make good sense, one can ques-
tion its necessity and desirability. In fact,
there may be a study design that allows
simultaneous evaluation of the new tech-
nology and implementation of the opti-
mal diagnostic strategy. In other words,
performance of the study ideally not only
helps assess the new technology but at
the same time improves clinical practice
through some form of a self-organizing
feedback system (37). In a self-organizing
feedback system, adjustments of physi-
cian ordering behavior, of the technol-
ogy used, and of the interpretation take
place as a result of feedback loops.
The above list of problems and ques-
tionable assumptions suggests that we
should think of a study design for the
evaluation of new diagnostic imaging
technology that gets away from our focus
on cohort validation studies to evaluate
sensitivity and specificity. So, is there a
study design that can address the issues
listed?
CRITERIA FOR THE
ASSESSMENT AND
IMPLEMENTATION OF NEW
DIAGNOSTIC IMAGING
TECHNOLOGY
The goal of a study to evaluate new diag-
nostic imaging technology is to help us
decide whether the new technology pro-
vides value for money and to enable im-
plementation of the new technology in a
timely fashion. To achieve this goal the
following criteria must be met: (a) The
study should demonstrate that the new
diagnostic strategy facilitates the clinical
decision-making process. (b) The process
of data collection should be integrated
into clinical practice. (c) By the end of the
study, the optimal diagnostic strategy
should have been implemented in clini-
cal practice through a self-organizing
feedback system. (d) The study should be
fast and require only limited resources.
(e) The study should demonstrate that
the new diagnostic strategy leads to
equivalent or better outcomes for the pa-
tient. (f) The study should demonstrate
that the cost of the new diagnostic strat-
egy is either the same as or less than that
of the strategy it is replacing or that the
benefits to the patient or cost savings
downstream are so large that we can af-
ford to pay for the new test.
STUDY DESIGN: AN EMPIRICAL
RCT
We propose assessing diagnostic imaging
technology with an empirically based
study design. To minimize the bias intro-
duced by extraneous factors and ensure
an unbiased comparison with a control
group, we propose using an RCT design
whenever feasible and ethical. Outcomes
measured would need to reflect the
global goal of performing the imaging
test in the clinical context under consid-
eration. An essential feature of our pro-
posed study design is that we propose
taking into account the dimension
“time” when analyzing the outcome
measures. We will discuss each of these
issues in turn.
Empirical Study
Our goal of timely implementation of
valuable new diagnostic imaging tech-
nology could potentially be achieved if
we strive for concurrent implementation
and assessment of the new technology.
That is, the process of performing the
trial should lead not only to evaluation
of the new diagnostic strategy in compar-
ison with the old strategy but also to
implementation of the new strategy if it
is better. The trial design should, in our
opinion, be empirically based and prag-
matic; that is, the trial should be inte-
grated into clinical practice rather than
be implemented in a strictly controlled,
but probably unrealistic, experimental
setting.
In general, current clinical practice
would be used as the control strategy for
the study. We recognize that current clin-
ical practice is, in many instances, un-
structured and that documentation of
relevant information may be lacking.
Clearly, sloppy clinical practice will not
suffice as the control strategy. Ideally,
performance of the study will help struc-
ture and streamline clinical practice, ini-
tiate collection of relevant information,
and enhance communication between
physicians mutually and between physi-
cians and their patients.
Randomization across Diagnostic
Strategies
As with all studies, the inclusion and
exclusion criteria should guarantee selec-
tion of a representative group of patients
for the diagnostic problem under consid-
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eration. The tradeoff is between recruit-
ing a fairly homogeneous group of pa-
tients that is clearly identifiable versus
ensuring that the study is sufficiently
generalizable (38).
After recruiting patients that fulfill the
inclusion criteria, we propose random as-
signment of patients to the new diagnos-
tic strategy or to the old strategy. For
example, if we want to evaluate CT an-
giography versus intraarterial angiogra-
phy for peripheral arterial disease, we
would randomly assign patients with pe-
ripheral arterial disease to undergo either
initial CT angiography or intraarterial
digital subtraction angiography (DSA)
(Fig 3). In this empirical design, we
would allow for further evaluation with
other imaging technology should the
need arise. For example, if CT angiogra-
phy does not provide sufficient diagnos-
tic information to establish a therapeutic
plan, the patient would undergo (selec-
tive) intraarterial angiography.
Randomizing Discordant Test
Results
Randomization after inclusion and
prior to the initial diagnostic test is the
most straightforward practical approach.
It may not, however, always be the most
efficient approach, because a large pro-
portion of the patients will not contrib-
ute to a difference in outcome. An alter-
native design is to study all patients with
both tests (both CT angiography and in-
traarterial DSA) and randomly assign
only those patients with discordant test
results (ie, CT and intraarterial DSA yield
discrepant results). Although this may be
a more efficient design (ie, fewer patients
required for the study), the logistics of
such a design are far more complicated,
and the results may lead to interpretation
problems.
For example, in this clinical setting the
test result is not a dichotomous yes/no
result but rather a treatment choice out
of a range of possible treatments, includ-
ing bypass surgery with various possible
proximal and distal anastomotic sites,
percutaneous transluminal angioplasty
or stent placement at various sites, com-
binations of surgical and percutaneous
procedures, or no revascularization pro-
cedure. The treatment choice is further
influenced by local preferences and ex-
pertise and by the patient’s preferences.
Thus, what constitutes a discrepancy in
the test results is not easily defined. Fur-
thermore, if both tests have been per-
formed, information from the test that is
not supposed to influence management
will invariably become known to the
treating physicians in a proportion of
cases, in part indirectly because the treat-
ing physician will know that the other
test yielded a discrepant result (otherwise
this patient would not have been ran-
domly assigned) and in part because in-
formation that is withheld for research
reasons can always be requested on ethi-
cal grounds. Finally, interpretation of the
results may be hampered by the fact that
the diagnostic work-up itself may influ-
ence not only the choice of treatment but
also the manner in which the treatment
is performed (eg, if a CT angiographic
image is available to guide catheteriza-
tion, the procedure may be performed
differently than if no prior noninvasive
imaging information is available).
Randomization between Providing
Test Results versus Not Providing
Test Results
An alternative to randomizing across
diagnostic strategies would be to use the
new diagnostic strategy in all patients
but only provide the test results to the
treating physician and patient for those
randomly assigned to the new diagnostic
strategy. This approach facilitates recruit-
ment of patients because all patients will
be offered the new technology, which
tends to increase their willingness to par-
ticipate. Furthermore, this approach could
potentially reduce a biased follow-up if pa-
tients are more willing to respond to ques-
tionnaires after participation in a new di-
agnostic strategy. The authors of one
published study (39) used this approach to
determine the value of MR imaging for
help in assessing fetal-pelvic proportions in
breech presentation and demonstrated
that the information obtained with MR
imaging increased the number of success-
ful vaginal deliveries and reduced the
number of emergency cesarean sections.
The main caveat of this approach is
similar to that of randomization of dis-
crepant test results. Information from the
new test will invariably become known
to the treating physicians in a proportion
of cases in the group where it was not
supposed to influence management ac-
cording to the study protocol. Part of the
problem is the logistics of keeping test
results secret, but this can be overcome
with the correct procedures in place.
More important, information withheld
for research reasons can be requested for
an individual patient on ethical grounds,
and if the diagnostic test has been per-
formed already it is a small step for the
treating physician to insist on getting the
information. Finally, if the new test is
associated with a risk, even a small one, it
may be considered unethical to perform
such a test when the test result does not
have any influence on the care of the
patient.
Figure 3. Schematic shows study design for an empirical RCT to
compare CT angiography (CTA) with intraarterial DSA (Angio) for
pretreatment diagnostic imaging work-up of peripheral arterial dis-
ease. After randomization, either CT angiography or intraarterial an-
giography (in a few cases followed immediately by percutaneous
transluminal angioplasty or stent placement [/-PTA/stent]) is per-
formed. The imaging findings are discussed at the vascular confer-
ence. The imaging work-up is required to help determine the optimal
treatment: percutaneous transluminal angioplasty, stent placement,
bypass surgery, or exercise therapy. The dotted arrows indicate where
subjective experience is expected to influence the clinical process.
duplex  duplex ultrasonography, /-  with or without.
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A Nonrandomized Design
Although in general we would recom-
mend an RCT design, some situations
may justify a modified design. Some-
times the potential study population is so
small that randomization does not seem
feasible within a limited time frame.
Sometimes the new diagnostic strategy
is far safer or far less burdensome to
the patient than the currently used diag-
nostic test. Sometimes preliminary re-
ports from other institutions have al-
ready demonstrated good results with
the new diagnostic strategy, making ran-
domization unethical or impossible be-
cause of patient preferences and physi-
cian bias.
A nonrandomized design would imply
that, first, the new test would be performed
in addition to the current work-up to “fine
tune” the technical details of performing
the examination and to familiarize physi-
cians (both radiologists and clinicians)
with the new diagnostic imaging technol-
ogy. During this phase the current work-up
should be established in protocol form and
documented. Approximately 10–20 cases
would probably suffice for this first phase.
Next, the new diagnostic strategy should
be implemented as the initial test. Physi-
cians are given the option of requesting the
previously used test if they believe it is nec-
essary to complete the work-up, but such
requests are recorded and tracked. The pro-
cess is documented over time as physicians
become familiar with the new test.
Outcome Measures and Trends over
Time
As mentioned, we consider the trial to
be a vehicle to implementation of the
best diagnostic imaging technology. We
propose evaluating the implementation
process by including outcome measures
that reflect the clinical decision-making
process based on the imaging informa-
tion and acceptance of the new test. Be-
cause physicians’ experience with and
opinions of the test change over time, all
outcome measures would have to be
tracked over time. Crucial to our pro-
posed study design is to measure out-
comes that reflect the learning curve and
acceptance of the new diagnostic strategy
over time. Thus, taking into account the
dimension “time” is an essential feature
of our proposed study design.
Furthermore, the outcome measures
should focus on the goal of performing
the diagnostic trial and should therefore
measure the clinical decision-making
process. Outcome measures that reflect
the goal of the trial include the probabil-
ity that additional studies would be or-
dered, the costs of the diagnostic work-up
and treatment, the physicians’ confidence
in therapeutic decision making, patient
outcome measures related to the clinical
problem at presentation, and, in the event
of a randomized trial, the recruitment rate.
Percentage (and type) of additional re-
quested tests and trends over time.—One
would expect that this percentage is prac-
tically constant over time for the control
(ie, currently used) diagnostic work-up
strategy and variable over time for the
experimental strategy. For example, in
the course of an implementation study of
CT angiography compared with intraar-
terial DSA for peripheral arterial disease,
one would expect the percentage of re-
quested intraarterial DSA procedures fol-
lowing CT angiography to be high ini-
tially (probably about 90%) and to
decrease over time as interventional radi-
ologists and vascular surgeons become
more familiar with this technology for
this particular indication. In other words,
the proportion of intraarterial DSA pro-
cedures requested would reflect the learn-
ing curve of performing and interpreting
CT angiographic images. Furthermore,
one would expect that after initial CT
angiography, a requested angiogram could
be limited to a selective study. It is even
conceivable that with the introduction of
CT angiography, physicians will request
CT angiography after intraarterial DSA to
solve specific diagnostic problems. The
latter would demonstrate a shift in the
control strategy over time that would
support the use of the new technology.
Costs of diagnostic work-up and treatment
and trends over time.—Resource utilization
and the associated costs of the diagnostic
work-up and treatment should be re-
corded, and the trends over time should
be calculated (Fig 4). As indicated, it is
likely that crossovers will occur, in that
patients undergoing the experimental
strategy may still need additional work-up
with (part of) the control strategy. In addi-
tion, patients undergoing the control strat-
egy may require additional work-up,
which may, over time, be performed more
and more with the experimental strategy.
If the diagnostic strategy influences the
treatment approach, this effect would need
to be estimated. For example, the availabil-
ity of CT angiographic images prior to a
combined intraarterial DSA–angioplasty
procedure could potentially lead to a more
focused selective diagnostic procedure and
a more direct approach to the interven-
tional procedure.
Medical costs can be estimated by mul-
tiplying resource utilization and the cost
per unit of resource. The cost per unit of
resource—that is, per diagnostic or ther-
apeutic procedure—should be deter-
mined with cost accounting that takes
into consideration the initial investment
of equipment, investments during use,
maintenance, years of use, discounting,
number of procedures per year, person-
nel costs, room rent, housekeeping, ad-
ministration, and other overhead costs
(13,31).
Figure 4. Graph shows expected trends in costs of diagnostic
work-up and treatment. Patients undergoing the experimental strat-
egy, in this example CT angiography (CTA), may still need additional
work-up with the control strategy, intraarterial DSA (Angio). As phy-
sicians gain more experience with the new technology over time,
additional examinations will probably be required less often, and the
costs of the work-up with the experimental strategy will decrease.
Patients undergoing the control strategy may require additional
work-up, which may, over time, be performed more and more with
the experimental strategy.
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Confidence in therapeutic decision making
and trends over time.—The diagnostic and
therapeutic decisions made and the phy-
sicians’ confidence with their therapeutic
decision making are additional useful out-
come measures (Fig 5). The physicians’
confidence may be measured by using a
rating scale or a visual analogue scale
(40,41). One would expect that their con-
fidence is constant over time for the con-
trol (currently used) diagnostic work-up
strategy. For the experimental strategy one
would expect their confidence initially to
be lower than that of the control strategy
and to increase over time as they become
more familiar with the new technology.
Confidence could, however, decrease over
time if initial expectations of the new tech-
nique are not fulfilled as the limitations of
the technology become apparent.
Patient outcomes.—To track whether po-
tentially treatable disease is inadvertently
missed when the experimental strategy is
used, patients must be followed up for a
period of time during which the false-neg-
ative outcomes would be apparent. For pe-
ripheral arterial disease, for example, 6
months would be appropriate. Patients
with persistent symptoms would return
within this period. During follow-up, pa-
tient outcomes should be assessed by re-
searchers blinded to the allocated strategy.
Patient outcome measures should include
survival, symptoms, quality-of-life mea-
sures, and events, including the percentage
of patients that cross over from initial con-
servative therapy to revascularization be-
cause of persistent symptoms (42,43). If CT
angiography does not fail to demonstrate
treatable disease, we would expect patient
outcomes and the percentage of crossovers
to be the same for the two strategies.
The recruitment rate as function of time
since the start of the study.—One of the
outcome measures in our proposed study
design is the percentage of eligible pa-
tients actually recruited for the study as a
function of time since the start of the
study (Fig 6). As long as the two strategies
are considered to be equivalent, physi-
cians will be comfortable with random
assignment of patients across the diag-
nostic work-up strategies. Any trend
identified in the proportion of patients
recruited should be interpreted in the
context of all factors that may influence
recruitment. For example, during the
course of the trial physicians may be-
come reluctant to recruit patients with-
out palpable femoral pulses and may in-
stead request CT angiography. Despite
strict inclusion and exclusion criteria, a
subtle change in those considered eligi-
ble for the trial may occur. Furthermore,
patients may pick up subtle nonverbal
information during the informed con-
sent procedure and, as a result, be unwill-
ing to participate.
Both physicians’ reluctance to recruit
patients and patients’ refusal to partici-
pate will be noticable in the recruitment
rate. Although a change in recruitment
rate will not change the internal validity
of the trial, the generalizability of the
results must be considered in light of the
changing indication for the procedures
evaluated. In accordance with the Con-
solidated Standards of Reporting Trials,
or CONSORT, statement for the report-
ing of RCTs (44), we propose tracking the
number of potentially eligible, the num-
ber actually eligible, and the number re-
cruited patients over time. A criterion for
stopping the study could be based on the
percentage of potentially eligible patients
recruited for the study. For example, if at
the outset 70% of potentially eligible pa-
tients are recruited, and after 6 months
only 20% are recruited, then the subjec-
tive experience of the physicians will
probably have influenced recruitment,
provided, of course, that other logistic
problems have not arisen.
Data Collection
The data that would need to be col-
lected in the context of the described trial
for peripheral arterial disease include the
following:
1. Date of presentation, date of comple-
tion of the diagnostic work-up (ie, date of
last imaging study), diagnostic tests per-
formed, date and type of the treatment
decision, date of treatment, date that nor-
mal activities are resumed, date of recur-
rence of symptoms and severity of those
symptoms, and type of events.
2. All patients with peripheral arterial
disease evaluated by the vascular surgery
staff would need to be registered and
baseline characteristics recorded to en-
able the evaluation of generalizability
Figure 5. Graph shows expected trends in confidence in decision
making. The physicians’ confidence may be measured by using a
rating scale or visual analogue scale. One would expect that their
confidence is constant over time for the control strategy (intraarterial
DSA [Angio] in this example). For the experimental strategy of CT
angiography (CTA), one would expect their confidence initially to be
lower than that for the control strategy and to increase over time as
they become more familiar with the new technology.
Figure 6. Graph shows the recruitment rate as a function of time
since the start of the study. As long as the two strategies are consid-
ered equivalent, physicians will be comfortable with patients being
randomly assigned to treatment. If, over time, it becomes clear from
clinical experience that use of one of the diagnostic imaging strate-
gies is preferable, physicians will be reluctant to recruit patients for
the trial. Despite strict inclusion and exclusion criteria, a subtle
change in those considered eligible for the trial may take place. A
criterion for stopping the study (arrow) could be based on the per-
centage of potentially eligible patients recruited for the study.
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and the proportion eligible and propor-
tion randomly assigned.
3. Patient characteristics and diagnos-
tic test results should be documented, in-
cluding age, sex, symptoms (according to
the Rutherford classification), and find-
ings on CT and/or intraarterial DSA images
(including lesion severity, lesion length, le-
sion location, and runoff). These variables
are used in evaluation of the randomiza-
tion process and to help analyze temporal
changes in clinical decisions made.
4. If reproducibility of interpretation is
an issue, the images should be inter-
preted by at least two independent ob-
servers.
5. Diagnostic and therapeutic deci-
sions made must be tracked for each pa-
tient during the vascular conference, as
must confidence in the decision. The lat-
ter can be recorded on a rating scale from
zero to 10, with zero indicating no con-
fidence and 10 indicating full confidence
in the decision (41).
6. Quality of life should be measured at
baseline, 6 weeks, 3 months, and 6
months, with a general descriptive instru-
ment (eg, MOS 36-Item Short-Form Health
Survey), a disease-specific descriptive in-
strument (eg, the VascuQol), and an eval-
uative instrument providing general popu-
lation values (eg, the EuroQol) (45–48).
7. Resource utilization of diagnostic
procedures must be tracked and a de-
tailed cost analysis should be performed
for all procedures that are important (eg,
CT and DSA) by recording the time re-
quired to perform the procedure, the per-
sonnel involved, and the materials
needed. Other costs per unit of resource
can be analyzed independently of patient
data collection.
8. Resource utilization for therapeutic
procedures should be tracked with case
record forms and complemented with
data from the hospital information sys-
tem and the patient questionnaires.
Data Analysis
Analogous to the intention-to-treat prin-
ciple for analysis of therapeutic RCTs, the
data of a diagnostic RCT should be ana-
lyzed on an intention-to-diagnose-and-
treat basis. This implies that once a pa-
tient has been randomly assigned, he or
she will remain in the assigned group for
the analysis irrespective of whether cross-
over occurred to the other strategy and of
whether follow-up was complete or not.
The underlying concept is that patients
that cross over and patients lost to fol-
low-up are part and parcel of the strategy.
Essential in the analysis of data from a
study that involves concurrent imple-
mentation and evaluation of a new diag-
nostic strategy is determination of trends
among outcome measures over time. By
including time since the start of the
study in the analysis, we have a surrogate
for the learning curve of physicians and
we can adjust for this effect. The analysis
can be performed pragmatically by using
multivariable regression analysis to model
costs of the diagnostic work-up, costs of
the diagnostic work-up plus treatment,
and physicians’ confidence in the thera-
peutic decision. Multivariable logistic re-
gression analysis can be used to model
the probability of additional examina-
tions requested and the recruitment rate.
In both models, the independent vari-
ables include the diagnostic strategy;
time since the start of the study; an in-
teraction term between these two; and
covariates such as symptoms, age, and
sex. In a randomized design, the focus of
the analysis would be to demonstrate a
difference between the two groups, tak-
ing into account the trend over time. In
the absence of a concurrent randomized
control group, the analysis of trends over
time is the primary focus of the analysis.
Randomization and selected use of the
traditional test does not preclude the pos-
sibility of obtaining estimates of the sen-
sitivity and specificity of a new test in
comparison with those of the traditional
test as reference standard. Because the
test results are verified only in selected
cases, we would need to use a method
that adjusts for the associated possible
verification bias (26–29). This requires
development of a logistic regression
model to predict the probability of veri-
fication as a function of age, sex, disease
severity, and time since start of the study.
The probability of verification is then
used to adjust the data and calculate cor-
rected estimates of sensitivity and speci-
ficity.
DISCUSSION
The linear approach of the hierarchical
assessment of diagnostic imaging tech-
nology is a reflection of the philosophy
prevalent in the industrial period (Fig 1).
A serial approach leads from technical
development through various steps of
technology assessment to implementa-
tion. In the postindustrial philosophy, an
interwoven circular approach with con-
current development, assessment, and
implementation of technology is more
appropriate (Fig 7) (37,49). Initial techni-
cal development of new technology is
followed by rapid implementation, and
assessment begins concurrently. Assess-
ment leads to adjustments in the number
of requests for examinations and sugges-
tions for refinement of the technology,
which is the feedback mechanism that
adjusts implementation and initiates
technical development. This interwoven
circular approach with feedback loops is
typical of cybernetics and self-organizing
systems (37).
The key features of our proposed study
design (Table) are randomization, an em-
pirically based pragmatic study protocol,
an interweaving of research and clinical
practice, outcome measures that focus on
the clinical decision-making process, and
measurement of trends over time in the
outcome measures. These key features
have both advantages and disadvantages
that we will discuss.
Randomization for evaluating diagnos-
tic tests is not novel, but, apart from
screening trials, it has seldomly been
Figure 7. Diagram illustrates the concept of an interwoven, circular,
self-organizing approach to development, assessment, and imple-
mentation of new diagnostic imaging technology.
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used for comparing diagnostic imaging
modalities (39,50,51). Sometimes, ran-
domization across diagnostic strategies in
fact means randomization across man-
agement strategies that include both di-
agnostic work-up and treatment (52).
This is clearly the case in screening trials
in which not only the value of the diag-
nostic test but also the benefit of early
diagnosis and treatment of the disease
are being evaluated. The advantage of
randomization clearly lies in the reduc-
tion of bias due to extraneous factors in
the comparison between experimental
and control groups.
Randomization also has disadvantages,
however. The inherent limitations of
randomization are reduced generalizabil-
ity of study results due to the selected
patient population and a perceived ne-
cessity to strictly control the experimen-
tal setting. Generalizability of trial results
to other settings can be ensured by in-
cluding a wide range of patients in the
trial. Furthermore, by using an empirical
pragmatic design we in fact study daily
clinical practice, which increases general-
izability.
Ethical considerations are frequently
mentioned as an argument against ran-
domization. If there are good reasons to
believe that one diagnostic imaging mo-
dality is superior to another, then ran-
domization is clearly unethical. In such
situations, the inferior test should not be
performed because of the possibility of
misleading results, risks, and costs, and a
trial is unnecessary. In fact, if the avail-
able evidence demonstrates that a new
diagnostic strategy is superior, the results
of the trial may even be misleading, or, at
the very least, the research resources used
are not justified relative to the scientific
information obtained (35). Furthermore,
if the tests are very different in their us-
age and goal (eg, D-dimer and spiral CT
for help in diagnosing pulmonary embo-
lism), then randomization between these
two tests is neither useful nor feasible.
Randomization between two full diag-
nostic strategies that include these tests,
however, is feasible. In evaluating new,
less invasive tests in the context of exist-
ing screening programs, randomization
between the reference standard and the
new test is ethical only if the available
evidence suggests that the risk of missing
the disease is more or less an equivalent
impediment to the patient as are the risk
and discomfort of performing the refer-
ence standard. For example, in screening
patients with a history of premalignant
colon polyps by using colonoscopy, ran-
domization between colonoscopy and
virtual CT colonoscopy would be ethical
only if the reduced burden to the patient
of virtual colonoscopy is on the same
order of magnitude as the burden to the
patient of potentially missing a polyp.
Finally, in the very early stages of devel-
opment of a diagnostic technology and if
missing the diagnosis would be life
threatening, randomization between the
new test and the reference standard is
unacceptable.
More often than not, however, we
truly do not know which diagnostic strat-
egy is best, and diagnostic strategies have
both potential advantages and disadvan-
tages. Even obtaining all possible imag-
ing information can have disadvantages,
in that risks and burden are involved and
results can potentially be misleading. In
the example mentioned earlier, CT an-
giography may very well turn out to be
diagnostically superior to intraarterial
DSA, because multiple views can be ob-
tained to evaluate the vessels. Further-
more, CT angiography is less risky and
less burdensome than intraarterial DSA,
which favors the use of the former. At the
same time, however, physicians inter-
preting CT angiographic images may still
be uncomfortable with the images, and
artifacts may not be recognized as such.
By allowing the use of an alternative di-
agnostic technique in cases where diag-
nostic uncertainty persists, valuable tech-
nology is not withheld from the patient.
The premise is that physicians will re-
quest additional diagnostic examinations
until they have sufficient diagnostic in-
formation to formulate a treatment plan.
Furthermore, the patient may be exam-
ined with the alternative test if symp-
toms persist or recur during follow-up.
Finally, if we truly do not know which
test strategy is better, randomization will
at least ensure that 50% of patients will
be assigned to the better strategy.
Costs are also frequently brought up as
an argument against randomization. Ran-
domization between two diagnostic tests,
however, is less expensive than perform-
ing both tests in all patients. In fact, in
the example of intraarterial DSA versus
CT angiography, we claim that perform-
ing the trial may actually reduce the ex-
pense of the diagnostic imaging work-up
for peripheral arterial disease in compar-
ison with the expense of not performing
the trial! If the trial had not been initi-
ated, the work-up would continue to be
performed with intraarterial DSA in all
patients. Through randomization, half of
all patients with peripheral arterial dis-
ease are initially evaluated with CT an-
giography, which, as the initial test, is
clearly less expensive than intraarterial
DSA. Depending on how often intraarte-
rial DSA is performed after CT angiogra-
phy, this can lead to a cost reduction.
Furthermore, after CT angiography, an
additional intraarterial DSA examination
can often be limited to selective views,
and an interventional procedure can usu-
ally be planned concurrently, which can
lead to additional cost savings. The only
real research expenses are those associ-
ated with data collection, data analysis,
and reporting of the results—but that is a
cost that will be incurred irrespective of
Key Features of Proposed Study Design for Concurrent Development,
Assessment, and Implementation of New Imaging Technology
Feature Explanation
Randomization Random assignment to either current diagnostic
strategy (control) or new technology strategy
(experimental); minimizes bias by extraneous factors
Empirical and pragmatic Document effect on clinical decision making; feedback
helps improve imaging protocol and postprocessing;
feedback may influence recruitment rate
Self-organizing system Subjective experience influences further technical
development and adjustment of implementation
Integration Integrate research and clinical practice in an interwoven
process
Trend analysis Outcome measures analyzed as function of time since
start of study; demonstration of trends is a key result
Process-oriented outcome measures Outcome measures should reflect clinical decision-
making process and could include trends in
(a) additional examinations requested, (b) costs of
diagnostic work-up and therapy, (c) physician
confidence in decision making, (d) recruitment rate
Patient outcomes Include measures that reflect overall goal of health care:
(a) quality of life, recurrent symptoms, events;
(b) crossovers to other diagnostic strategy during
follow-up
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whether the trial is designed as a ran-
domized or a nonrandomized trial. The
proposed trial design will likely be
funded by agencies interested in funding
technology assessment, implementation,
and translational research. We have been
successful in obtaining funding from
such an agency to perform the study de-
scribed in this article.
An empirically based pragmatic study
protocol may be frowned on by research-
ers—it refutes the notion that research
should be performed in a strictly con-
trolled setting. An empirical pragmatic
study protocol may be influenced by sub-
jective experience and individuals’ opin-
ions. Through feedback, we allow subjec-
tive experience to affect the postprocessing
methods of the imaging study and the in-
terpretation of images. Furthermore, we al-
low feedback to influence requests for ad-
ditional examinations. The question is
whether this empirical pragmatic ap-
proach invalidates the results of the trial.
Our premise in allowing feedback to influ-
ence the clinical process under evaluation
is that it will happen anyway—if not ex-
plicitly, it will happen implicitly. It is im-
possible to prevent an increase in experi-
ence and knowledge among technologists
and physicians using the new techniques,
and changes will take place, although
sometimes in a subtle way. In general, a
scientist cannot play the role of a detached
objective observer but becomes involved in
the world he or she observes (49).
Similarly, we can question whether we
want to separate the clinical process and
research. Rather than struggle to create a
“pure” experimental setting, we question
whether creating a pure experimental
setting is desirable. One of the frequently
expressed complaints about research is
the delay between the reporting of results
and the implementation thereof. Then
why not integrate the clinical process
and the research that is meant to im-
prove that process? Why not make it into
one interwoven whole? The clinical re-
searcher is intricately involved in the
clinical process, and, therefore, it would
make immanent sense to integrate clini-
cal research and clinical practice into one
interwoven process (37).
Our chosen outcome measures are, in
part, subjective and may therefore be
prone to bias. Although this certainly
represents a limitation of our approach,
one should recognize that whatever we
measure is determined and colored by
our perception of the problem. For exam-
ple, if we choose to measure the ankle-
brachial blood pressure index (an objec-
tive outcome measure) to determine the
severity and progression of peripheral ar-
terial disease, we will observe hemody-
namic changes due to obstruction in the
blood vessels to the legs. The fact that the
patient’s symptoms may be influenced
by the ability of muscle tissue to adapt to
ischemia, the ability of vessels to develop
collateral circulation, the patient’s gen-
eral fitness, and the patient’s psychologic
ability to cope with pain will remain un-
observed. By using the ankle-brachial in-
dex as measure of disease severity, we
have defined the problem of peripheral
arterial disease as analogous to the prob-
lem encountered by a plumber. Thus, our
choice of outcome measure is in itself
subjective. We perceive the world from
our own viewpoint, and our observations
probably say more about how we have
defined the problem and categorized the
possible outcomes than about the actual
phenomena we observe (49).
Ideally, one would want to observe
phenomena from multiple perspectives.
Putting all the different perspectives to-
gether will give an overall holistic pic-
ture. In choosing outcome measures for
our trial design, we have attempted to
capture the perspective of the patient by
measuring health-related quality of life
and events during follow-up, the per-
spective of the physician by measuring
his or her confidence in the diagnosis
and the decision whether or not to re-
quest further diagnostic examinations,
and the perspective of the health care
system by measuring the costs related to
the diagnostic work-up and therapy. De-
pending on the clinical problem, it may
be relevant to measure other outcomes as
well.
Most important of all, we propose us-
ing time as an important dimension in
the analysis of outcomes. Instead of mea-
suring cumulative outcomes, the key fea-
ture of our proposed study design is to
measure trends in outcomes over time.
There is always a learning curve to get
acquainted with new technology. Even
after implementation of a new technol-
ogy, adjustments are constantly made to
the technique used, and interpretation
skills keep developing. Thus, the devel-
opment of new technology continues as
we use it—and it should continue to de-
velop! If we force ourselves to adhere to
the exact same imaging protocol as the
one with which we initially started, we
will very quickly be using an outdated
technique. Apart from changes in the
technique used, it is impossible (and un-
desirable) to prevent interpreters from
learning from their experience. Thus, in-
stead of forcing the imaging technique
and interpretation to remain stable and
stationary, we propose using time as an
explanatory variable in the data analyses,
which will model the learning curve,
technical developments, and increasing
interpretation skills over time.
Our proposed approach is not a pana-
cea: It has both advantages and limita-
tions. As with every technique, model,
and theory, this design will have to find
its place among the multitude of study
designs available. The approach seems es-
pecially useful when available evidence
based on results from small clinical stud-
ies, exploratory decision- and cost-effec-
tiveness analyses, and clinical experience
suggests that two diagnostic strategies are
similar, that both have advantages and
disadvantages, that defining a reference
standard proves to be difficult, or that the
new technology could potentially sur-
pass the existing reference standard. Fur-
thermore, we would suggest the integra-
tion of structured data collection into
daily clinical practice for the purpose of
assessment of imaging technology and
randomization between diagnostic strat-
egies, rather than performance of new
imaging tests in addition to the currently
used tests. This enables assessment of
new imaging technologies as they be-
come available for clinical use.
In conclusion, for the development,
assessment, and implementation of new
diagnostic imaging technology, we pro-
pose use of a randomized empirical trial
design based on a pragmatic study proto-
col that interweaves research and clinical
practice. Outcome measures should in-
clude measures related to the clinical de-
cision-making process, costs, and patient
health outcomes. The key feature of our
approach is to measure the trends over
time in the outcome measures.
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